Bristol Taking A Cautious Approach To Triple Immuno-Oncology Combos
This article was originally published in The Pink Sheet Daily
Executive Summary
The company is starting to explore triple immuno-oncology combinations, Head of Oncology-Global Clinical Research Jean Viallet said, but IO development is mainly focused on expanding the firm's existing double combination, Opdivo and Yervoy, to earlier treatment and new tumors.
You may also be interested in...
Bristol Hits Sweet Spot On Checkpoint Inhibitor Combination Pricing
Decision to price combo of Yervoy and Opdivo at just 6% more than Yervoy monotherapy could set a trend for the market.
The 10 US Biosimilar Launches That Could Drive Big Savings By 2027
Biosimilar versions of drugs like Humira, Stelara and Eylea are among the products that could generate cumulative sales of $129bn over the next five years, according to IQVIA.
Pfizer Returns Bavencio Rights To Merck KGaA, Closing An IO Era
The arrangement ends a nearly 10-year collaboration between Pfizer and Merk KGaA on the PD-L1 inhibitor that, despite some success, never reached its ultimate goal.